Literature DB >> 2431665

Extrapleural pneumonectomy for diffuse, malignant mesothelioma.

M J DaValle, L P Faber, C F Kittle, R J Jensik.   

Abstract

Extrapleural pneumonectomy for malignant mesothelioma is a radical procedure that entails en bloc removal of the parietal pleura, lung, pericardium, and diaphragm. Minimal tumor remains after this procedure; palliation and occasional long-term survival may be achieved in properly selected patients. Extrapleural pneumonectomy for diffuse, malignant mesothelioma was done in 33 patients (27 male and 6 female) with 18 procedures on the left side and 15 on the right. There was a history of exposure to asbestos in 16 (48%) of the patients. Histological classification revealed that 20 tumors were epithelial, 10 were mixed, and 3 were sarcomatous. Good palliation, defined as survival for 24 months with a return to fairly normal activities, was obtained in 8 patients (24%) and survival for 36 months was achieved in 5 patients. Three patients died of the disease at 59 months, 60 months, and 82 months. There were 3 operative deaths (9.1%), and serious postoperative complications occurred in 8 patients (24%). Postoperative adjunctive therapy consisting of chemotherapy or irradiation or both was given to approximately one-half of the patients. These findings indicate that extrapleural pneumonectomy for malignant mesothelioma can be done with an acceptable morbidity and mortality. Palliation is achieved in 24% of patients, and there may be an occasional long-term survivor.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2431665     DOI: 10.1016/s0003-4975(10)64593-6

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  10 in total

Review 1.  [Problems in diagnosis and therapy of malignant pleural mesothelioma].

Authors:  A Türler; S P Mönig; M Raab
Journal:  Med Klin (Munich)       Date:  1997-02-15

Review 2.  Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.

Authors:  Emanuela Taioli; Maaike van Gerwen; Meredith Mihalopoulos; Gil Moskowitz; Bian Liu; Raja Flores
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

3.  Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma. A treatment option in selected cases?

Authors:  K Takahashi; J Yoshida; M Nishimura; K Nagai
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-02

4.  [Pleural mesothelioma--problems in diagnosis and clinical course in 25 patients].

Authors:  F Liewald; L Sunder-Plassmann; H Dienemann; J Mezger
Journal:  Langenbecks Arch Chir       Date:  1989

5.  Diffuse malignant pleural mesothelioma: a multi-institutional clinicopathological study.

Authors:  Akira Iyoda; Toshikazu Yusa; Chikabumi Kadoyama; Kazuyoshi Sasaki; Hideki Kimura; Hisami Yamakawa; Mitsutoshi Shiba; Takehiko Fujisawa; Ichiro Yoshino
Journal:  Surg Today       Date:  2008-10-29       Impact factor: 2.549

6.  Chemosensitivity and cytokine sensitivity of malignant mesothelioma.

Authors:  R V Bowman; L S Manning; M R Davis; B W Robinson
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 7.  Diffuse malignant mesothelioma of the pleura: a clinicopathological study of six patients with a prolonged symptom-free interval or extended survival after biopsy and a review of the literature of long-term survival.

Authors:  E J Mark; D H Shin
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 8.  Cerebral metastases in pleural mesothelioma: case report and review of the literature.

Authors:  M Wroński; M Burt
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

9.  An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.

Authors:  G Falkson; M Hunt; E C Borden; J A Hayes; C I Falkson; T J Smith
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

10.  Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies.

Authors:  P Baas; L Murrer; F A Zoetmulder; F A Stewart; H B Ris; N van Zandwijk; J L Peterse; E J Rutgers
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.